Patient group input requested for new Rapid Reviews on medicinal products for COVID-19.

EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We believe patient groups can help us understand patients’ unique perspectives by collecting and presenting patients’ […]

Patient group input requested for a new Joint Assessment on a medicinal product for cerebral adrenoleukodystrophy (CALD).

This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen or mechanical venilation. This Rapid Collaborative Review aims to define, according to the national […]

EUnetHTA Implementation – Final Report now available

The Final Report on Implementation, a deliverable of EUnetHTA Joint Action 3 (2016-2021), explores the use of joint assessments (JA) and collaborative assessments (CA) during JA3 and compares this with the use of assessment products during Joint Action 2 (2012-2015). By examining how JA and CA processes have affected implementation, the report outlines the extent […]

PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity

This is the pharmaceutical Joint Assessment PTJA08 – on siponimod for the treatment of active SPMS. In January 2020, the European Commission granted marketing authorisation for Mayzent® (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. This Joint Assessment […]

PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant

This is the pharmaceutical Joint Assessment PTJA06 – on polatuzumab vedotin for the treatment of relapsed/refractory DLBCL. In January 2020, The European Commission granted conditional marketing authorisation for Polivy® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) […]

Important Event Dates – 2020/21

​We would like to confirm some dates for key EUnetHTA events throughout the remainder of JA3. Please ensure to put these in your agenda: 25-26 March, 2020 – Heads of Agencies Meeting (Spring 2020) 1-2 April, 2020 – EUnetHTA Assembly & Forum 2020 29-30 October, 2020 – Heads of Agencies Meeting (Autumn 2020) 4-5 March, 2021 – Heads of Agencies Meeting […]

OTCA22 – Final Assessment Report and related documents now available

The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Point-of-care Tests (POCT): D-Dimer and Troponin’ are now available for access. Troponin and D-dimer point of care tests can be used to aid the diagnosis of patients with symptoms suggestive of suspected acute coronary syndrome and venous thromboembolism respectively. This report aimed […]

November 2019 Implementation Report – Now Available

EUnetHTA is pleased to announce ​the new Implementation Report with Appendices are now available for access. ​The report covers the updated use and uptake on all Joint Action 3 assessments. The report and all related documentation is available at this link, or via the National Uptake and Case Studies visuals here.

OTCA17 – Final Assessment Report and related documents now available

The final assessment report and related documents for the Other Technologies Collaborative Assessment ‘Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH)’ are now available for access. The present assessment addressed the research question whether the lithium triborate (LBO) laser for photoselective vaporisation of the […]